I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma with an unchanged $39 price target, citing an expanded late-stage pipeline and strong balance sheet from $115M financing. Key catalysts include FDA interactions and IND submissions for NXP100/200. Separately, Maxim Group also maintained a Buy rating with a $30 target.
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Nuvectis Pharma and keeping the price target at $39.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Joseph Pantginis has given his Buy rating due to a combination of factors, including Nuvectis Pharma’s broadened late-stage pipeline and clear U.S. regulatory roadmap. The company’s in-licensing of NXP100 and NXP200, coupled with China’s first approval of NXP100 for treatment-naïve PNH, supports a de-risked development profile and enhances long-term value potential.
Near-term catalysts such as planned FDA pre-IND interactions and 4Q26 IND submissions for both NXP100 and NXP200, as well as upcoming NXP200 data at ESMO, provide multiple opportunities for value inflection. In addition, the strengthened balance sheet following the $115M follow-on financing extends the cash runway into 1H29, enabling execution across NXP900 combination studies and the expanded portfolio; accordingly, Pantginis reiterates his $39 price target, unchanged from prior levels.
In another report released on July 24, Maxim Group also reiterated a Buy rating on the stock with a $30.00 price target.